Notice to attend the Annual General Meeting held on May 19, 2026 in Isofol Medical AB (publ)
Regulatory
Isofol optimizes the design of its phase Ib/II study following new regulatory approval
Non regulatory
Isofol Medical AB (publ) publishes annual report and corporate governance report for 2025
Regulatory
Isofol receives gross proceeds of 18.9 MSEK in connection with the exercise of warrants and guarantee commitments for warrants of series TO1, and resolves on a directed share issue
Regulatory
Isofol secures license rights for arfolitixorin in autism
Regulatory
The subscription price for warrants of series TO1 in Isofol has been set at SEK 0.48 and the exercise period commences on 16 March 2026
Regulatory
Isofol receives top guarantee commitment and letters of intent corresponding to 42 percent of upcoming warrant exercise
Regulatory
Isofol’s Nomination Committee proposes election of Christian Haglund as new Board Director
Regulatory
Isofol presents at investor meetings in March
Non regulatory
Isofol provides update on the ongoing phase Ib/II clinical study of arfolitixorin
Regulatory
Isofol Medical AB (publ) publishes year-end report, January – December 2025
Regulatory
Isofol participates in the ASCO GI congress
Non regulatory
Isofol participates in several investor meetings in December and January
Non regulatory
European Patent Office intends to grant a new patent for Isofol’s arfolitixorin
Non regulatory
Isofol Medical AB (publ) publishes interim report, January–September 2025
